AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15181565 — intervention group
Group type: EXPERIMENTAL
Intervention: rIFN-gamma 1b (100 microg) and rIFN-gamma 1b (200 microg) combined
Number of subjects: 75
Study 11352127 — intervention group
Group type: EXPERIMENTAL
Intervention: Postmenopausal hormone replacement therapy (HRT)
Number of subjects: 96
Study 11352127 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estradiol
Number of subjects: 96
Study 11352127 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 96
Study 9609431 — intervention group
Group type: EXPERIMENTAL
Intervention: Premedication with pronase
Number of subjects: 100
Study 9609431 — intervention group
Group type: COMPARATOR
Intervention: Dimethylpolysiloxane alone
Number of subjects: 100
Study 9609431 — intervention group
Group type: COMPARATOR
Intervention: Dimethylpolysiloxane plus sodium bicarbonate
Number of subjects: 100
Study 11644558 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomised controlled trial treatment protocol
Number of subjects: 0
Study 11644558 — intervention group
Group type: COMPARATOR
Intervention: Randomised controlled trial
Number of subjects: 0
Study 2187486 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Number of subjects: 20
Study 2187486 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 88984 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenoxybenzamine
Number of subjects: 0
Study 88984 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31253234 — intervention group
Group type: EXPERIMENTAL
Intervention: Trials that reported results by sex or gender
Number of subjects: 45
Study 31253234 — intervention group
Group type: COMPARATOR
Intervention: Trials that did not report results by sex or gender
Number of subjects: 45
Study 26838769 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week low-caloric diet (intense weight loss)
Number of subjects: 19
Study 26838769 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight maintenance (4 weeks after initial weight loss)
Number of subjects: 19
Study 26838769 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 18)
Number of subjects: 19
Study 26132586 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 61
Study 26132586 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic adjustable gastric banding (LAGB)
Number of subjects: 61
Study 26132586 — intervention group
Group type: COMPARATOR
Intervention: Intensive lifestyle weight loss intervention
Number of subjects: 61
Study 26132586 — intervention group
Group type: EXPERIMENTAL
Intervention: RYGB
Number of subjects: 61
Study 26132586 — intervention group
Group type: EXPERIMENTAL
Intervention: LAGB
Number of subjects: 61
Study 23322462 — intervention group
Group type: COMPARATOR
Intervention: Bilateral controlled shoes with no insoles
Number of subjects: 51
Study 23322462 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral wedge insoles laterally posted by 5°
Number of subjects: 51
Study 20607425 — intervention group
Group type: EXPERIMENTAL
Intervention: Auto-adjusting bi-level mode (VAuto™)
Number of subjects: 22
Study 20607425 — intervention group
Group type: COMPARATOR
Intervention: Standard bi-level mode
Number of subjects: 22
Study 19231043 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-lipoic acid (ALA) 200 mg
Number of subjects: 60
Study 19231043 — intervention group
Group type: COMPARATOR
Intervention: Placebo (vehicle)
Number of subjects: 60
Study 16768834 — intervention group
Group type: EXPERIMENTAL
Intervention: Soya isoflavones (50 mg/d)
Number of subjects: 30
Study 16768834 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 15815568 — intervention group
Group type: EXPERIMENTAL
Intervention: Education (ED)
Number of subjects: 75
Study 15815568 — intervention group
Group type: EXPERIMENTAL
Intervention: Education and telephone case management (ED + TCM)
Number of subjects: 75
Study 15815568 — intervention group
Group type: COMPARATOR
Intervention: Standard care (SC)
Number of subjects: 75
Study 12963609 — intervention group
Group type: EXPERIMENTAL
Intervention: Docosahexaenoic acid supplementation (400 mg/d)
Number of subjects: 44
Study 12963609 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 12963609 — intervention group
Group type: EXPERIMENTAL
Intervention: Docosahexaenoic acid supplementation
Number of subjects: 44
Study 10693491 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based nursing
Number of subjects: 0
Study 10693491 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized controlled trial (RCT)
Number of subjects: 0
Study 10693491 — intervention group
Group type: EXPERIMENTAL
Intervention: Quasi-legal model based on reflection
Number of subjects: 0
Study 7588509 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fibre diet (rye bran bread and whole-grain rye crispbread)
Number of subjects: 8
Study 7588509 — intervention group
Group type: COMPARATOR
Intervention: Low-fibre diet (wheat-flour bread)
Number of subjects: 8
Study 2137233 — intervention group
Group type: EXPERIMENTAL
Intervention: Rimantadine hydrochloride (RH)
Number of subjects: 301
Study 2137233 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 301
Study 6446442 — intervention group
Group type: COMPARATOR
Intervention: DMPA
Number of subjects: 239
Study 6446442 — intervention group
Group type: EXPERIMENTAL
Intervention: NET-ENT
Number of subjects: 239
Study 12086759 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose BEAM and transplantation of haemopoietic stem cells (BEAM‐HSCT)
Number of subjects: 161
Study 12086759 — intervention group
Group type: COMPARATOR
Intervention: Dexa‐BEAM (dexamethasone and carmustine, etoposide, cytarabine, and melphalan)
Number of subjects: 161
Study 12086759 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival for both treatments
Number of subjects: 161
Study 31899499 — intervention group
Group type: EXPERIMENTAL
Intervention: Home exercise intervention delivered by a physical therapist with 6 home visits over 8 months and monthly calls, exercising ≥3 times weekly
Number of subjects: 141
Study 31899499 — intervention group
Group type: COMPARATOR
Intervention: Attentional control group receiving equal attention
Number of subjects: 141
Study 29667763 — intervention group
Group type: EXPERIMENTAL
Intervention: Dutasteride 0.5 mg
Number of subjects: 117
Study 29667763 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117
Study 29667763 — intervention group
Group type: EXPERIMENTAL
Intervention: Dutasteride 0.5 mg (open-label)
Number of subjects: 117
Study 27439911 — intervention group
Group type: EXPERIMENTAL
Intervention: Carfilzomib, lenalidomide, and dexamethasone (KRd)
Number of subjects: 792
Study 27439911 — intervention group
Group type: COMPARATOR
Intervention: Lenalidomide and dexamethasone (Rd)
Number of subjects: 792
Study 24906519 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted TKA (group NAV)
Number of subjects: 200
Study 24906519 — intervention group
Group type: COMPARATOR
Intervention: Conventional TKA (group REG)
Number of subjects: 200
Study 22241704 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based constraint-induced therapy
Number of subjects: 22
Study 22241704 — intervention group
Group type: COMPARATOR
Intervention: Traditional rehabilitation
Number of subjects: 22
Study 20937130 — intervention group
Group type: EXPERIMENTAL
Intervention: NGX-4010 (8% capsaicin patch)
Number of subjects: 155
Study 20937130 — intervention group
Group type: COMPARATOR
Intervention: 0.04% capsaicin control patch
Number of subjects: 155
Study 20937130 — intervention group
Group type: EXPERIMENTAL
Intervention: NGX-4010 (8% capsaicin patch) in patients with PHN for at least 6 months
Number of subjects: 155
Study 20937130 — intervention group
Group type: COMPARATOR
Intervention: 0.04% capsaicin control patch in patients with PHN for at least 6 months
Number of subjects: 155
Study 20937130 — intervention group
Group type: EXPERIMENTAL
Intervention: NGX-4010 (8% capsaicin patch) at week 12 in patients with PHN for at least 6 months
Number of subjects: 155
Study 20937130 — intervention group
Group type: COMPARATOR
Intervention: 0.04% capsaicin control patch at week 12 in patients with PHN for at least 6 months
Number of subjects: 155
Study 18824909 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic approach to weaning and extubation
Number of subjects: 318
Study 18824909 — intervention group
Group type: COMPARATOR
Intervention: Sole physician's judgment (control)
Number of subjects: 318
Study 16093411 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory stimuli
Number of subjects: 59
Study 16093411 — intervention group
Group type: COMPARATOR
Intervention: Visual stimuli
Number of subjects: 59
Study 16093411 — intervention group
Group type: COMPARATOR
Intervention: Cross-modal visual-auditory stimuli
Number of subjects: 59
Study 12057791 — intervention group
Group type: EXPERIMENTAL
Intervention: Slip-Coat cannula
Number of subjects: 50
Study 12057791 — intervention group
Group type: COMPARATOR
Intervention: Standard cannula
Number of subjects: 50
Study 12057791 — intervention group
Group type: EXPERIMENTAL
Intervention: Slip-Coat cannula (for women with no prior live births)
Number of subjects: 50
Study 12057791 — intervention group
Group type: COMPARATOR
Intervention: Standard cannula (for women with no prior live births)
Number of subjects: 50
Study 9932855 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride 0.3 mg/kg four times a day for 8 weeks
Number of subjects: 69
Study 9932855 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 7551831 — intervention group
Group type: EXPERIMENTAL
Intervention: Pivmecillinam
Number of subjects: 0
Study 7551831 — intervention group
Group type: COMPARATOR
Intervention: Norfloxacin
Number of subjects: 0
Study 1969196 — intervention group
Group type: EXPERIMENTAL
Intervention: Local analgesics (lignocaine)
Number of subjects: 0
Study 1969196 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical analgesic cream (EMLA)
Number of subjects: 0
Study 7451917 — intervention group
Group type: EXPERIMENTAL
Intervention: Single extraamniotic dose of F2-alpha prostaglandin gel
Number of subjects: 0
Study 7451917 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 0
Study 31985294 — intervention group
Group type: EXPERIMENTAL
Intervention: CinnoRA® (40 mg subcutaneous injection)
Number of subjects: 74
Study 31985294 — intervention group
Group type: COMPARATOR
Intervention: Humira® (40 mg subcutaneous injection)
Number of subjects: 74
Study 31985294 — intervention group
Group type: EXPERIMENTAL
Intervention: CinnoRA®
Number of subjects: 74
Study 31985294 — intervention group
Group type: COMPARATOR
Intervention: Humira®
Number of subjects: 74
Study 31060602 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab
Number of subjects: 163
Study 31060602 — intervention group
Group type: COMPARATOR
Intervention: High density of CD8+ cells in non-ICT patients
Number of subjects: 163
Study 27794137 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged sitting with intermittent walking
Number of subjects: 19
Study 27794137 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged sitting with intermittent standing exercises
Number of subjects: 19
Study 27794137 — intervention group
Group type: COMPARATOR
Intervention: Uninterrupted sitting
Number of subjects: 19
Study 26036466 — intervention group
Group type: EXPERIMENTAL
Intervention: S-1 daily administration (Arm A)
Number of subjects: 0
Study 26036466 — intervention group
Group type: EXPERIMENTAL
Intervention: S-1 alternate-day administration (Arm B)
Number of subjects: 0
Study 24184429 — intervention group
Group type: EXPERIMENTAL
Intervention: sertraline at standard dosing + CBT
Number of subjects: 47
Study 24184429 — intervention group
Group type: EXPERIMENTAL
Intervention: sertraline titrated slowly + CBT
Number of subjects: 47
Study 24184429 — intervention group
Group type: COMPARATOR
Intervention: pill placebo + CBT
Number of subjects: 47
Study 21615714 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital placement of Foley catheter
Number of subjects: 42
Study 21615714 — intervention group
Group type: COMPARATOR
Intervention: Speculum placement of Foley catheter
Number of subjects: 42
Study 19293796 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening with PSA
Number of subjects: 43842
Study 19293796 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening with PSA (excluding overdiagnosed cases)
Number of subjects: 43842
Study 16674782 — intervention group
Group type: EXPERIMENTAL
Intervention: Partnership care model intervention
Number of subjects: 0
Study 16674782 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 14656837 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated external defibrillator (AED) use by first responders
Number of subjects: 469
Study 14656837 — intervention group
Group type: COMPARATOR
Intervention: Control group (no AED use)
Number of subjects: 469
Study 10699684 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimization method for random allocation of patients
Number of subjects: 13
Study 10699684 — intervention group
Group type: EXPERIMENTAL
Intervention: Zelen's method for randomization
Number of subjects: 13
Study 8852869 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous sodium lactate infusions
Number of subjects: 9
Study 8852869 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusions
Number of subjects: 9
Study 2049259 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (300 mg four times daily)
Number of subjects: 12
Study 2049259 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine (150 mg twice daily)
Number of subjects: 12
Study 2049259 — intervention group
Group type: COMPARATOR
Intervention: Cifenline alone (160 mg)
Number of subjects: 12
Study 6363798 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin, 25 mg four times daily for 3 weeks
Number of subjects: 24
Study 6363798 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 6363798 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 24
Study 31512500 — intervention group
Group type: EXPERIMENTAL
Intervention: Devimistat (2000 mg/m2) in combination with high dose cytarabine and mitoxantrone
Number of subjects: 0
Study 31512500 — intervention group
Group type: COMPARATOR
Intervention: High dose cytarabine and mitoxantrone alone
Number of subjects: 0
Study 27826107 — intervention group
Group type: EXPERIMENTAL
Intervention: dual-tDCS
Number of subjects: 22
Study 27826107 — intervention group
Group type: COMPARATOR
Intervention: sham
Number of subjects: 22
Study 24584609 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated Peritoneal Dialysis (APD)
Number of subjects: 15
Study 24584609 — intervention group
Group type: COMPARATOR
Intervention: Continuous Ambulatory Peritoneal Dialysis (CAPD)
Number of subjects: 15
Study 24584609 — intervention group
Group type: COMPARATOR
Intervention: Comparison of total clearance and mass removal (MR)
Number of subjects: 15
Study 24584609 — intervention group
Group type: COMPARATOR
Intervention: Protein-bound solutes
Number of subjects: 15
Study 23031656 — intervention group
Group type: EXPERIMENTAL
Intervention: Codeine
Number of subjects: 1071
Study 23031656 — intervention group
Group type: COMPARATOR
Intervention: Meloxicam
Number of subjects: 1071
Study 23031656 — intervention group
Group type: COMPARATOR
Intervention: Nimesulide
Number of subjects: 1071
Study 23031656 — intervention group
Group type: COMPARATOR
Intervention: Benzydamine
Number of subjects: 1071
Study 23031656 — intervention group
Group type: COMPARATOR
Intervention: Rofecoxib
Number of subjects: 1071
Study 23031656 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol
Number of subjects: 1071
Study 21792073 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative real-time polymerase chain reaction-based assay using a predictor of survival from 91 genes
Number of subjects: 101
Study 21792073 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative real-time polymerase chain reaction-based assay for stage 1 patients
Number of subjects: 101
Study 19451554 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan, 16 mg/d increasing to 32 mg/d
Number of subjects: 5221
Study 19451554 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5221
Study 16945857 — intervention group
Group type: EXPERIMENTAL
Intervention: Intentional learning condition (searching for the underlying rule with feedback)
Number of subjects: 0
Study 16945857 — intervention group
Group type: COMPARATOR
Intervention: Incidental learning condition (memorizing a set of grammatical tunes)
Number of subjects: 0
Study 15560811 — intervention group
Group type: EXPERIMENTAL
Intervention: Enamel matrix derivatives (EMD) applied in test subjects
Number of subjects: 172
Study 15560811 — intervention group
Group type: COMPARATOR
Intervention: No EMD applied in control subjects
Number of subjects: 172
Study 15560811 — intervention group
Group type: EXPERIMENTAL
Intervention: EMD applied in test subjects
Number of subjects: 172
Study 15560811 — intervention group
Group type: COMPARATOR
Intervention: Both EMD and no EMD
Number of subjects: 172
Study 11742907 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic saline solution (4.5%) inhalation
Number of subjects: 16
Study 11742907 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline solution (0.9%) inhalation
Number of subjects: 16
Study 9602598 — intervention group
Group type: EXPERIMENTAL
Intervention: Cuffed oropharyngeal airway (COPA)
Number of subjects: 20
Study 9602598 — intervention group
Group type: COMPARATOR
Intervention: Tracheal tube (TT)
Number of subjects: 20
Study 7973107 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulised salbutamol (5 mg) given 4 times daily for 24 hours on 2 consecutive days
Number of subjects: 22
Study 7973107 — intervention group
Group type: COMPARATOR
Intervention: Saline given 4 times daily for 24 hours on 2 consecutive days
Number of subjects: 22
Study 7973107 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulised salbutamol (5 mg)
Number of subjects: 22
Study 2659302 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrose-containing snacks (7% of total daily calories)
Number of subjects: 16
Study 2659302 — intervention group
Group type: COMPARATOR
Intervention: Aspartame-sweetened snacks (1% of total daily calories)
Number of subjects: 16
Study 30980248 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-daily smokers
Number of subjects: 1916
Study 29354957 — intervention group
Group type: EXPERIMENTAL
Intervention: Fire needle plus chemotherapy
Number of subjects: 60
Study 29354957 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 60
Study 26145718 — intervention group
Group type: EXPERIMENTAL
Intervention: Chiropractic SMT
Number of subjects: 70
Study 26145718 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sham manipulation)
Number of subjects: 70
Study 23273236 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education program
Number of subjects: 153
Study 23273236 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 153
Study 21247529 — intervention group
Group type: EXPERIMENTAL
Intervention: MLN1202
Number of subjects: 0
Study 21247529 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18271771 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical therapy with 0.2% minocycline
Number of subjects: 33
Study 18271771 — intervention group
Group type: COMPARATOR
Intervention: Placebo aqueous solution mouthwash
Number of subjects: 33
Study 17071204 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning (IP group, n = 27)
Number of subjects: 54
Study 17071204 — intervention group
Group type: COMPARATOR
Intervention: Intermittent vascular occlusion (IVO group, n = 27)
Number of subjects: 54
Study 12430110 — intervention group
Group type: COMPARATOR
Intervention: Single stimulation group (30 mL local anesthetic injected after locating 1 motor response)
Number of subjects: 80
Study 12430110 — intervention group
Group type: EXPERIMENTAL
Intervention: Multistimulation group (10 mL local anesthetic injected on each of 3 motor responses)
Number of subjects: 80
Study 12430110 — intervention group
Group type: EXPERIMENTAL
Intervention: Multistimulation group
Number of subjects: 80
Study 10087113 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous injection of mangafodipir trisodium (Mn‐DPDP) at a dosage of 5 micromol/kg.
Number of subjects: 18
Study 7552592 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral allopurinol (20 mg/ml) for seven daily doses
Number of subjects: 400
Study 7552592 — intervention group
Group type: COMPARATOR
Intervention: Placebo (equivalent dose) for seven daily doses
Number of subjects: 400
Study 7552592 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral allopurinol (20 mg/ml)
Number of subjects: 400
Study 2210808 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mmol sodium chloride added to a low salt diet (20 mmol NaCl/day) for 1 week
Number of subjects: 40
Study 2210808 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium citrate (200 mmol sodium/day) as a supplement to the low salt diet for a third week
Number of subjects: 40
Study 2210808 — intervention group
Group type: COMPARATOR
Intervention: Low salt diet (20 mmol NaCl/day)
Number of subjects: 40
Study 6933738 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg cyproterone acetate at weekly intervals
Number of subjects: 16
Study 6933738 — intervention group
Group type: COMPARATOR
Intervention: 100 mg oestradiol‐17 beta‐undecylate every month
Number of subjects: 16
Study 6151553 — intervention group
Group type: EXPERIMENTAL
Intervention: Prizidilol hydrochloride (200‐300 mg b.i.d.)
Number of subjects: 13
Study 31348732 — intervention group
Group type: EXPERIMENTAL
Intervention: Language-specific attention treatment (L-SAT)
Number of subjects: 4
Study 31348732 — intervention group
Group type: COMPARATOR
Intervention: Direct attention training (DAT)
Number of subjects: 4
Study 28772105 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercial sugar-sweetened beverage (SSB) consumption
Number of subjects: 11
Study 28772105 — intervention group
Group type: COMPARATOR
Intervention: Sedentary SSB consumption
Number of subjects: 11
Study 28772105 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 minutes of aerobic exercise followed by SSB consumption
Number of subjects: 11
Study 28772105 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 minutes of aerobic exercise followed by water consumption
Number of subjects: 11
Study 28772105 — intervention group
Group type: COMPARATOR
Intervention: Water consumption
Number of subjects: 11
Study 26814620 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BTX‐A) 200U subcutaneous injection
Number of subjects: 40